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The aim of this work was to study the anti-Candida activity of lidocaine and nitroglycerin alone and in combination. Ten Candida
strains were included, corresponding to 1 collection type strain (ATCC 10231) and 9 clinical isolates: 4 C. albicans,2C. glabrata,1
C. tropicalis,1C. krusei, and 1 C. parapsilosis. The CLSI reference M27-A3 micromethod was used to determine the anti-Candida
activity of the drugs alone; minimal inhibitory and lethal concentrations were determined. The classic checkboard technique was
used to determine the activity of combined drugs. Lidocaine fungicidal eﬀect was dosedependent. Nitroglycerin exhibited a higher
eﬀect. The drugs combination resulted in a reduction of the inhibitory concentration, corresponding to an additive eﬀect. In
conclusion, both drugs exhibited an interesting anti-Candida activity. The combination of lidocaine with nitroglycerin was shown
to have an additive eﬀect against Candida spp., predicting the interest to include, in the future, these drugs in a new delivery system
for the treatment of mucocutaneous candidosis.
1.Introduction
Candida spp. are microorganisms frequently found in the
human oral cavity, gastrointestinal tract, and vagina [1–4].
Among mucocutaneous infections, vulvovaginal candidosis
(VVC) is the second most frequent vaginal infection, after
vaginal bacteriosis and is one of the most common clinical
diseases caused by Candida spp. It aﬀects 70–75% of women
at least once in their lifetime while 40–50% of them will
experience a recurrence; 5–8% of adult women develop
recurrent vulvovaginal candidosis (RVVC), deﬁned as four
or more episodes within a year [3–7]. The main goal of VVC
treatment is the control and immediate relief of its signs
and symptoms, related to vulvovaginal inﬂammation, as
quickly as possible and the mycological cure to be conﬁrmed
some days later; recurrence prevention is also pursued [8].
VVC is usually treated very eﬀectively with azoles, which
are present in the most prescribed therapeutic regimens,
unless a suspected or conﬁrmed azole-resistant Candida
strain is involved. On the other hand, most gynecologists
believe that the control of RVVC requires both systemic
and local therapy, also involving new antifungal drugs and
strategies [3, 9, 10]. Despite RVVC being considered a
Candida infection that is more dependent on the host
characteristics, therapeutics approaches available and able
to allow a remission of the symptoms between episodes are
antifungal drugs used for a long period of time [8, 9, 11].
Some authors consider that new therapeutic strategies must
be considered for RVVC control [3, 9, 10]. In addition to the
limited number of available antifungal drugs, the restrictions
to its use stress the need for the development and validation
of new therapeutic strategies exhibiting distinct mechanisms
of action and/or evasion of resistance [12–15].
Lidocaine is used as anesthetic, and its anti-Candida
activity has been previously reported as a fungicidal drug
exhibiting a dose-dependent eﬀect and related with a2 Infectious Diseases in Obstetrics and Gynecology
primary lesion of the cytoplasmic membrane [12]. Also its
ability to inhibit Candida albicans germ tube formation
was reported [16]. Nitroglycerin has been used to treat
haemorrhoidal symptoms under an ointment pharmaceuti-
cal formulation, commercially available as Rectogesic [17].
An association of lidocaine with isosorbide-di-nitrate has
also been proposed for the treatment of anorectal problems
[18] on behalf of the expected beneﬁts of combining their
individual properties, namely, anaesthetic and blood supply
promoter.
As in VVC, irritation leads to excoriations and ﬁssuring
[19]. We investigated the in vitro anti-Candida activity of
lidocaine and nitroglycerin, both alone and in combination,
in view of its possible future inclusion in a pharmaceutical
formulation for the treatment of mucocutaneous candidosis.
2.MaterialsandMethods
2.1. Chemicals and Drugs. Pure and analytic grade com-
pounds were used to prepare the tested solutions used in this
work.A6%lidocainesolutionwaspreparedbysolubilization
of lidocaine cloridrate (Sigma-Aldrich, Portugal) in sterile
water. Stock solution of 1% glycerol trinitrate (Merck, Ger-
many) was used to prepare the work solution, meaning 0.5%
nitroglycerin in RPMI 1640 culture medium (Biochrom AG,
Berlin). Serial concentrations of the products were obtained
by geometric dilution in RPMI.
2.2. Yeast Strains. A total of 10 Candida strains were used,
including 5 C. albicans,2C. glabrata,1C. tropicalis, 1C .
krusei,and1C.parapsilosis.Withexceptionofthetypestrains
C. albicans ATCC 10231 from the American Type Culture
Collection, all the other strains tested were isolates from
patients with RVVC and showed variable degree of resistance
toﬂuconazole(Table 1).Suchisolateshadbeencharacterized
t os p e c i e sl e v e lu s i n gA P II D3 2( B i o M ´ erieux, Vercieux,
France), and its susceptibility pattern to classic antifungals
(ﬂuconazole and amphotericin B) was determined according
to the CLSI M27-A3 micromethod. The strains were kept
frozen in Brain-Heart Broth (Difco Laboratories, Detroit,
MI, USA) with 5% glycerol at −70◦C until testing. After
thawing, the strains were subcultured twice on Sabouraud
agar (Difco) to assure optimal growth (37◦C/24h).
2.3. Anti-Candida Activity. The lidocaine and nitroglycerin
anti-Candida activity was assessed according to the CLSI
reference M27-A3 micromethod protocol [20]. Minimal
inhibitory concentration (MIC) values were read visually
after 48h of incubation at 37◦C. For each tested concentra-
tion, yeast growth was compared with the positive control
(growth control). Only the total growth inhibition was
considered as MIC. All determinations were performed in
duplicate, and only concordant results from three indepen-
dent experiments were considered.
The modiﬁed protocol proposed by Canton et al.
[21] was used to determine minimal lethal concentrations
(MLCS).
2.4. Anti-Candida Activity of Lidocaine Plus Nitroglycerin.
The classical checkerboard methodology, as described by
Vitale et al. [22], was used to determine the MIC resulting
from the products association. One C. albicans ATCC
10231 was included. Brieﬂy, a two-dimensional microplate
with 50µlo fe a c hp r o d u c tw a sp r e p a r e d ;m i c r o p l a t e sw e r e
incubated during 24h at 37 ◦C.
MIC for products association was calculated from three
independent experiences with concordant results. To eval-
uate the compound interactions, the fractional inhibitory
concentration index (FICI) was calculated as follows: (MIC
of Drug A in combination/MIC of Drug A alone) + (MIC
of Drug B in combination/MIC of Drug B alone). The
interpretation of the FICI corresponds to a synergic eﬀect
for values ≤0.5: additive eﬀect when >0.5 but <4.0 and
antagonism when ≥4.0 [22].
3. Results and Discussion
Lidocaine and nitroglycerin exhibited antifungal activity
upon Candida s p p .M I Cv a ri e df r o m1 0m g / m Lt o3 0m g / m L
for lidocaine and from 0.15mg/mL to 0.30mg/mL for nitro-
glycerin(Table 2).Theantifungalsusceptibilitypatternofthe
selected strains to classical antifungals, namely, ﬂuconazole
and amphotericin B, was unrelated to the tested compounds
activity, predicting distinct mechanisms of action.
Lidocaine fungicidal eﬀect was conﬁrmed for concen-
trations corresponding to at least double MIC, varying
from 15mg/mL to 30mg/ml, showing a dose-dependent
eﬀect. C. krusei and C. albicans ATCC10231 were the most
susceptible strains to lidocaine (MIC 10mg/mL). Other C.
albicans exhibited an increased MIC, 15mg/mL, similar toC.
parapsilosis. On the other hand, C. glabrata and C. tropicalis
were the less susceptible, having their growth inhibited
by lidocaine at 20mg/mL. Our results are in accordance
with other authors that conﬁrm the higher C. albicans
susceptibility to this drug [12]. However, some MIC and
MLC diﬀerences were noticed (onefold dilution). This is
probably related to the fact that those authors choose the
macromethod from the same protocol that we used for the
micromethod.
Regarding nitroglycerin, the eﬀect was fungicidal at
concentrations able to inhibit Candida growth, being MIC
and MLC coincident. C. albicans was the most susceptible
species tested (0.15mg/mL). Other species exhibited higher
MIC values (0.30mg/mL), coincident with MLC for C.
tropicalis, C. parapsilosis,a n dC. glabrata AP 426: lower to
MLC for C. glabrata AP 425 (0.6mg/mL) and C. krusei
(1.25mg/ml).
The possible antifungal advantage of the two products
association was studied by the checkerboard procedure
upon C. albicans.Ar e d u c t i o ne ﬀect was evident for both
MIC products (lidocaine alone—7,5 mg/mL, lidocaine in
combination—5 mg/mL; nitroglycerin alone—0,15mg/mL,
nitroglycerin in combination—0,075mg/mL) expressed by
the resulting FICI value (1.17) that corresponds to an
additive eﬀect (>0.5 and <4.0).Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Candida spp. origin and susceptible proﬁle to classic antifungals, namely, ﬂuconazole and amphotericin B. Minimal inhibitory
concentrations (MICS) are presented in µg/mL.
Species Origin Fluconazol MIC (µg/mL) Amphotericin B MIC (µg/mL)
C. albicans ATCC 10231 Collection 1 0.5
C. albicans AP440 Vaginal 0.25 0.25
C. albicans AP416 Vaginal <0.125 1
C. albicans AP437 Vaginal 2 0.5
C. albicans AP439 Vaginal 0.5 1
C. glabrata AP426 Vaginal 32 0.25
C. glabrata AP425 Vaginal 32 0.25
C. krusei AP3 Vaginal >64 0.5
C. tropicalis AP407 Vaginal 2 1
C. parapsilosis AP11 Vaginal 1 0.5
Table 2: Candida spp. susceptibility to nitroglycerin and lidocaine. Minimal inhibitory concentration (MIC) and minimal lethal
concentration (MLC) are presented in mg/mL.
Species Nitroglycerin Lidocaine
MIC MLC MIC MLC
C. albicans ATCC 10231 0.15 0.15 10.0 15.0
C. albicans MC440 0.15 0.15 15.0 20.0
C. albicans MC416 0.15 0.15 15.0 20.0
C. albicans MC437 0.15 0.15 15.0 20.0
C. albicans MC439 0.15 0.15 15.0 20.0
C. glabrata MC426 0.30 0.30 20.0 30.0
C. glabrata MC425 0.30 0.625 20.0 30.0
C. krusei OL103 0.30 1.25 10.0 20.0
C. tropicalis MC407 0.30 0.30 20.0 30.0
C. parapsilosis AP11 0.30 0.30 15.0 25.0
The possible pH variation with the addition of both
solutions to culture medium was limited by the tampon
eﬀect of the RPMI medium. Additionally, the pH value at
the drugs most concentrated conditions was measured and
conﬁrmed to be between 6.9 and 7.1, guarantying no pH
inﬂuence on the results.
4. Conclusions
In this study we tested the anti-Candida activity of lidocaine
and nitroglycerin alone and in combination in view of
their use as topical treatment of acute VVC. Nitroglycerin’s
vasodilator eﬀect may promote healing while at the same
time the anesthetic eﬀect of lidocaine may relief pain,
burning, and pruritus. Our results show that adding to
the well-known therapeutic eﬀects of these two individual
drugs an anti-Candida activity may also be relevant. The
combination of lidocaine with nitroglycerin showed to have
an additive eﬀect against Candida spp.
In the future, the development of a new delivery system
including both lidocaine and nitroglycerin at concentrations
higher than MIC values here reported and that allow
compounds to produce local eﬀect limiting possible systemic
absorption, stands up as an interesting approach for VVC
topical treatment. These in vitro studies showing their
signiﬁcant antifungal activity must now be followed by in
vivo studies in animal models, to evidence the eﬃcacy of this
cheap and believed to be safe new strategy.
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